文献速递骨质疏松与钙磷/甲状旁腺

地舒单抗注射延迟与骨密度反应:一项基于电子健康记录的研究

Delayed Denosumab Injections and Bone Mineral Density Response: An Electronic Health Record-based Study.
PubMed 文献 · J Clin Endocrinol Metab · 2020-01-01

该研究利用两家学术医院2010至2017年的电子病历,分析151例接受至少2剂60 mg地舒单抗的45岁以上患者,评估注射延迟与骨密度变化的关系。结果显示用药依从性良好者腰椎和全髋骨密度年化增幅均高于依从性中等和差者,注射间隔越长骨密度反应越不理想。

要点

  • 依从性良好者腰椎骨密度年化增幅3.9%,中等者3.0%,差者1.4%(趋势P=0.002)。
  • 依从性良好者全髋骨密度年化增幅2.1%,中等者1.3%,差者0.6%(趋势P=0.002)。
  • 地舒单抗注射间隔延长与脊柱和全髋骨密度反应欠佳相关。

核心结论

  • 地舒单抗注射间隔延长与脊柱和全髋骨密度反应欠佳相关,需要在真实世界中改善地舒单抗的及时给药策略。

研究设计与样本

  • 基于电子健康记录的研究,使用两家学术医院2010至2017年的电子病历,纳入45岁以上、至少使用2剂60 mg地舒单抗的患者。

主要发现

  • 共识别151例患者的938次地舒单抗注射,平均(SD)年龄69(10)岁,95%为女性。
  • 依从性良好者腰椎骨密度年化增幅3.9%,依从性中等者3.0%,依从性差者1.4%(趋势P=0.002)。
  • 依从性良好者全髋骨密度年化增幅2.1%,依从性中等者1.3%,依从性差者0.6%(趋势P=0.002)。

关键数值与推荐

  • 依从性良好定义为给药间隔≤7个月(药物覆盖比MCR≥93%)。
  • 依从性中等定义为给药间隔7至10个月(MCR 75%-93%)。
  • 依从性差定义为给药间隔≥10个月(MCR≤75%)。

临床怎么用

  • 原文结论提出需要在真实世界中改善地舒单抗的及时给药策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Discontinuation of denosumab leads to a rapid reversal of its therapeutic effect. However, there are no data regarding how unintended delays or missed injections of denosumab impact bone mineral density (BMD) response. OBJECTIVE: We examined the association of delays in injections of denosumab with BMD change. DESIGN: We used electronic medical records from two academic hospitals from 2010 to 2017. PARTICIPANTS: Patients older than 45 years of age and used at least 2 doses of 60 mg denosumab. Denosumab adherence was evaluated by the medication coverage ratio (MCR). Good adherence corresponds to a dosing interval ≤7 months (defined by MCR ≥93%), moderate adherence corresponds to an interval of 7 to 10 months (MCR 75%-93%), and poor adherence corresponds to an interval ≥10 months (MCR ≤75%). OUTCOME MEASURES: Annualized percent BMD change from baseline at the lumbar spine, total hip, and femoral neck. RESULTS: We identified 938 denosumab injections among 151 patients; the mean (SD) age was 69 (10) years, and 95% were female. Patients with good adherence had an annualized BMD increase of 3.9% at the lumbar spine, compared with patients with moderate (3.0%) or poor adherence (1.4%, P for trend .002). Patients with good adherence had an annualized BMD increase of 2.1% at the total hip, compared with patients with moderate (1.3%) or poor adherence (0.6%, P for trend .002). CONCLUSIONS: A longer interval between denosumab injections is associated with suboptimal BMD response at both spine and total hip. Strategies to improve the timely administration of denosumab in real-world settings are needed.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Lyu H, Zhao SS, Yoshida K, et al. Delayed Denosumab Injections and Bone Mineral Density Response: An Electronic Health Record-based Study. J Clin Endocrinol Metab. 2020. PMID: 31894244. doi:10.1210/clinem/dgz321

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。